Geron (LTS:0IV3) Accounts Payable & Accrued Expense : $43.88 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Geron Accounts Payable & Accrued Expense?

Geron's quarterly accounts payable & accrued expense declined from Sep. 2023 ($55.55 Mil) to Dec. 2023 ($46.47 Mil) and declined from Dec. 2023 ($46.47 Mil) to Mar. 2024 ($43.88 Mil).

Geron's annual accounts payable & accrued expense increased from Dec. 2021 ($36.52 Mil) to Dec. 2022 ($43.29 Mil) and increased from Dec. 2022 ($43.29 Mil) to Dec. 2023 ($46.47 Mil).

Geron Accounts Payable & Accrued Expense Historical Data

The historical data trend for Geron's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Accounts Payable & Accrued Expense Chart

Geron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

22.98

21.84

36.52

43.29

46.47

Geron Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															38.07	52.71	55.55	46.47	43.88

Geron Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Geron (LTS:0IV3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (LTS:0IV3) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

GERN:USA GON:Germany GON:Germany

Address

919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404

Website

https://www.geron.com

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

Geron (LTS:0IV3) Headlines

No Headlines